Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246951 | 0.93 | TSHR (0.45) | HCAR2TSHRALDH1A1HPGDATM | |
| SCHEMBL30268 | 0.89 | HCAR2 (0.59) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL30100815 | 0.89 | HCAR2 (0.59) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL246950 | 0.86 | HCAR2 (0.55) | HCAR2TSHRALDH1A1GAA | |
| Fumaric Acid SCHEMBL28457704 | 0.84 | HCAR2 (0.53) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL15218679 | 0.83 | HCAR2 (0.52) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL2116188 | 0.83 | HCAR2 (0.56) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL3925810 | 0.83 | TSHR (0.55) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL27407118 | 0.83 | HCAR2 (0.52) | HCAR2TSHRALDH1A1HPGDGAA | |
| SCHEMBL3925814 | 0.83 | TSHR (0.55) | HCAR2TSHRALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2334378-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | HCAR2 68/4885TSHR 4060/4885ALDH1A1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.